Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma

VBCC - July 2015, Vol 6, No 6 - ASCO 2015 Highlights
Wayne Kuznar

Chicago, IL—Lenvatinib (Lenvima) added to everolimus (Afinitor) extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone.

The OS finding was a secondary end point in this international, randomized, open-label study in 153 patients with metastatic RCC, reported Robert J. Motzer, MD, Attending Physician, Memorial Sloan Kettering Cancer Center, New York City, at the 2015 American Society of Clinical Oncology meeting.

“Although improved PFS benefit was observed in both lenvatinib-containing arms, the magnitude of the PFS, the high response rate, and the longer OS results speak to the high level of efficacy observed in this study for the combination,” he said.

In metastatic RCC, the activation of the fibroblast growth factor pathway has been proposed as a mechanism of escape from vascular endothelial growth factor (VEGF)-targeted therapies. Lenvatinib is a potent tyrosine kinase inhibitor of the VEGF receptors and fibroblast growth factor receptors.

The patients were randomized to lenvatinib 18 mg plus everolimus 5 mg daily; lenvatinib monotherapy 24 mg daily; or everolimus monotherapy 10 mg daily, and were treated until disease progression or unacceptable toxicity.

The median PFS was 14.6 months for lenvatinib plus everolimus, 7.4 months for lenvatinib alone, and 5.5 months for everolimus alone. The combination significantly improved PFS compared with everolimus, with a hazard ratio (HR) of 0.40 (P <.001). Lenvatinib monotherapy also significantly improved PFS compared with everoli­mus alone (HR, 0.61; P = .048).

The objective response rate was 43% with the combination of lenvatinib plus everolimus compared with 27% for lenvatinib alone and 6% for everolimus alone.

“Most of the responses were partial, although one complete remission was observed in the combination arm,” Dr Motzer noted. “The duration of objective response was quite long in the combination arm; the median was 13 months.”

At the planned OS analysis for the primary data cutoff in June 2014, the median OS was 25.5 months for the combination, 18.4 months for lenvatinib alone, and 17.5 months for everolimus alone.

In an updated OS analysis, the median OS was 25.5 months in the combination arm, 19.1 months with lenvatinib alone, and 15.4 months with everolimus alone.

The patients in the lenvatinib-containing arms had more grade 3 adverse events and similar grade 4 adverse events compared with everolimus. “Most toxicities were managed by dose modification,” he said.

Prominent grade 3 events associated with lenvatinib were diarrhea, fatigue, nausea, vomiting, and hypertension. Grade 3 diarrhea was 20% in the combination arm, “which highlights the need for recognition and management of this toxicity for the combination, in particular,” Dr Motzer pointed out.

Related Items
Hypermobility Syndrome Underrecognized, Requires Team-Based Management
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatic Diseases
Neuropathies in Rheumatic Diseases Encompass Wide Spectrum of Diagnoses
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatic Diseases
Patients with Rheumatoid Arthritis Cite Improvements in Pain, Quality of Life as Treatment Goals
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatoid Arthritis
Celecoxib Demonstrates Better Results than Acetaminophen in Patients with Low Back Pain
Wayne Kuznar
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Back Pain
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Emerging Therapies
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Emerging Therapies
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Breast Cancer
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Melanoma
NCCN Panel Examines Impact of the Presidential Election on Cancer Care
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 published on June 3, 2016 in NCCN Conference Highlights
Last modified: July 24, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology